Horvath Walsh, L. Elise Rider, Alex Piercy, James Pike, James Wilson, Samuel Pandya, Bhavik J. Medeiros, Bruno C.
Published in
Oncology and Therapy
IntroductionThere is limited understanding concerning the health-related quality of life (HRQoL) in acute myeloid leukemia (AML) patients. Due to an overlap of symptoms, it can be difficult to separate disease versus treatment-related effects. Study objectives were to understand the impact of factors that might influence patients’ HRQoL, assess the...
Singh, Manni Durairaj, Priya Yeung, Jensen
Published in
Oncology and Therapy
The category of this article was incorrectly published as an Original Research Article, when it should have been published as a Review.
Thomas, Xavier
Published in
Oncology and Therapy
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) that is cytogenetically characterized by a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion of the promyelocytic leukemia (PML) and retinoic acid receptor alpha (RARα) genes. Because patients with APL present a tenden...
Belluomini, Lorenzo Fiorica, Francesco Frassoldati, Antonio
Published in
Oncology and Therapy
The discovery of immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, and programmed cell death ligand 1 (PD-L1) inhibitors, atezolizumab and durvalumab, has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Concurrent radiotherapy (RT) is of particula...
Chan, Hiu Ting Chin, Yoon Ming Low, Siew-Kee
Published in
Oncology and Therapy
Cancer pharmacogenomics is the science concerned with understanding genetic alterations and its effects on the pharmacokinetics and pharmacodynamics of anti-cancer drugs, with the aim to provide cancer patients with the precise medication that will achieve a good response and cause low/no incidence of adverse events. Advances in biotechnology and b...
Takahashi, Shunji Kinuya, Seigo Nonomura, Norio Shinohara, Nobuo Suzuki, Kazuhiro Suzuki, Hiroyoshi Nakamura, Katsumasa Satoh, Takefumi Tateishi, Ukihide Yoneda, Toshiyuki
...
Published in
Oncology and Therapy
IntroductionThe incidence of prostate cancer in Japan continues to increase, necessitating the continued development of effective therapies and strategies. Recent advances in treatments have improved the prognosis of metastatic disease and highlighted the importance of treating bone metastases to reduce the incidence of skeletal complications and i...
Litmanovich, Adi Khazim, Khaled Cohen, Idan
Published in
Oncology and Therapy
Interleukin-1 (IL-1) has long been known to be a key mediator of immunity and inflammation. Its dysregulation has been implicated in recent years in tumorigenesis and tumor progression, and its upregulation is thought to be associated with many tumors. Overexpression of the IL-1 agonists IL-1α and IL-1β has been shown to promote tumor invasiveness ...
Cornford, Philip Jefferson, Kieran Cole, Owen Gilbody, John
Published in
Oncology and Therapy
IntroductionLuteinising hormone-releasing hormone agonist (LHRHa) injections are currently used in the treatment of advanced prostate cancer, but the frequency of injections may represent a burden to patients and healthcare services. The aim of this study was to collect real-world evidence about clinical and practical outcomes for patients with pro...
Criscuolo, Marianna Fianchi, Luana Maraglino, Alessio M. E. Pagano, Livio
Published in
Oncology and Therapy
Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of the disease, with these forms showing different deg...
Wang, Tian Qi Samuel, Joseph N. Brown, M. Catherine Vennettilli, Ashlee Solomon, Hannah Eng, Lawson Liang, Mindy Gill, Gursharan Merali, Zahra Tian, Chenchen
...
Published in
Oncology and Therapy
IntroductionSystematic documentation of chemotoxicities in outpatient clinics is challenging. Incorporating patient-reported outcome (PRO) measures in clinical workflows can be an efficient strategy to strengthen the assessment of symptomatic treatment toxicities in oncology clinical practice. We compared the adequateness, feasibility, and acceptab...
